

# Emily C Somers

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/112192/emily-c-somers-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68

papers

4,362

citations

36

h-index

66

g-index

72

ext. papers

5,309

ext. citations

6.3

avg, IF

5.41

L-index

#	Paper	IF	Citations
68	COVID-19 Outcomes Among Solid Organ Transplant Recipients: A Case-control Study. <i>Transplantation</i> , <b>2021</b> , 105, 128-137	1.8	35
67	Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e445-e454	11.6	235
66	Access and Cost-Related Nonadherence to Prescription Medications Among Lupus Patients and Controls: The Michigan Lupus Epidemiology and Surveillance Program. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1561-1567	4.7	1
65	Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 991-996	9.5	25
64	The prevalence and impact of pre-existing sleep disorder diagnoses and objective sleep parameters in patients hospitalized for COVID-19. <i>Journal of Clinical Sleep Medicine</i> , <b>2021</b> , 17, 1039-1050	3.1	11
63	Environmental and drug-induced lupus <b>2021</b> , 381-388		
62	Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 1078-1087	16.2	76
61	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , <i>The</i> , <b>2021</b> , 3, e707-e714	14.2	11
60	Global outbreak research: harmony not hegemony. <i>Lancet Infectious Diseases</i> , <i>The</i> , <b>2020</b> , 20, 770-772	25.5	22
59	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 529-556	9.5	135
58	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 461-488	4.7	54
57	Tocilizumab for treatment of mechanically ventilated patients with COVID-19 <b>2020</b> ,		28
56	Pregnancy and autoimmune diseases. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2020</b> , 64, 3-10	4.6	12
55	Dietary Omega Polyunsaturated Fatty Acid Intake and Patient-Reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 874-881	4.7	19
54	Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus - Michigan Lupus Epidemiology and Surveillance Program, 2014-2015. <i>Morbidity and Mortality Weekly Report</i> , <b>2019</b> , 68, 819-824	31.7	5
53	The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever. <i>Lupus</i> , <b>2018</b> , 27, 1123-1129	2.6	33
52	Infertility - Prevention and Management. <i>Rheumatic Disease Clinics of North America</i> , <b>2017</b> , 43, 275-285	2.4	7

51	Antinuclear antibody prevalence in a general pediatric cohort from Mexico City: discordance between immunofluorescence and multiplex assays. <i>Clinical Epidemiology</i> , <b>2017</b> , 9, 1-8	5.9	3
50	Pregnancy and autoimmune connective tissue diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2016</b> , 30, 63-80	5.3	39
49	Prenatal Omega-3 Supplementation and Eczema Risk among Offspring at Age 36 Months <b>2016</b> , 2,		8
48	Characterisation of an epigenetically altered CD4(+) CD28(+) Kir(+) T cell subset in autoimmune rheumatic diseases by multiparameter flow cytometry. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000147	4.6	15
47	Placental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnancies. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000134	4.6	60
46	Rheumatic autoimmune diseases in women and midlife health. <i>Womens Midlife Health</i> , <b>2015</b> , 1,	2.3	23
45	Incidence and prevalence of systemic lupus erythematosus among Arab and Chaldean Americans in southeastern Michigan: the Michigan Lupus Epidemiology and Surveillance Program. <i>American Journal of Public Health</i> , <b>2015</b> , 105, e74-9	5.1	24
44	Mercury Exposure and Antinuclear Antibodies among Females of Reproductive Age in the United States: NHANES. <i>Environmental Health Perspectives</i> , <b>2015</b> , 123, 792-8	8.4	50
43	Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 369-78	9.5	262
42	The circadian clock in oral health and diseases. <i>Journal of Dental Research</i> , <b>2014</b> , 93, 27-35	8.1	49
41	Patients with systemic lupus erythematosus and haematological malignancy at a tertiary care centre: timing, histopathology and therapy. <i>Lupus Science and Medicine</i> , <b>2014</b> , 1, e000051	4.6	10
40	Environmental exposures, epigenetic changes and the risk of lupus. <i>Lupus</i> , <b>2014</b> , 23, 568-76	2.6	74
39	Mercury levels in pregnant women, children, and seafood from Mexico City. <i>Environmental Research</i> , <b>2014</b> , 135, 63-9	7.9	49
38	Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies. <i>Lupus Science and Medicine</i> , <b>2014</b> , 1, e000034	4.6	15
37	Is pregnancy a risk factor for rheumatic autoimmune diseases?. <i>Current Opinion in Rheumatology</i> , <b>2014</b> , 26, 321-8	5.3	8
36	Overexpression of X-linked genes in T cells from women with lupus. <i>Journal of Autoimmunity</i> , <b>2013</b> , 41, 60-71	15.5	135
35	Developmental programming for allergy: a secondary analysis of the Mothers, Omega-3, and Mental Health Study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2013</b> , 208, 316.e1-6	6.4	12
34	Parental history of lupus and rheumatoid arthritis and risk in offspring in a nationwide cohort study: does sex matter?. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 525-9	2.4	26

33	In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 759-66	4.7	36
32	Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 4040-7		59
31	Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. <i>Gynecological Endocrinology</i> , <b>2012</b> , 28, 624-7 <sup>2.4</sup>		43
30	Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and lupus flare severity. <i>Journal of Autoimmunity</i> , <b>2012</b> , 38, J216-22	15.5	58
29	Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R22	5.7	65
28	Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility. <i>Clinical Medicine Insights Reproductive Health</i> , <b>2012</b> , 2012, 9-18	6.5	19
27	Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. <i>PLoS ONE</i> , <b>2012</b> , 7, e37000	3.7	99
26	A polymorphism in the interleukin-4 receptor affects the ability of interleukin-4 to regulate Th17 cells: a possible immunoregulatory mechanism for genetic control of the severity of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2011</b> , 13, R15	5.7	21
25	Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 151-6	2.4	112
24	Do selected drugs increase the risk of lupus? A matched case-control study. <i>British Journal of Clinical Pharmacology</i> , <b>2010</b> , 70, 588-96	3.8	44
23	Effects of prasterone (dehydroepiandrosterone) on markers of cardiovascular risk and bone turnover in premenopausal women with systemic lupus erythematosus: a pilot study. <i>Lupus</i> , <b>2010</b> , 19, 1229-36	2.6	14
22	Ultrasound of the knee during voluntary quadriceps contraction: a technique for detecting otherwise occult effusions. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 725-9	4.7	23
21	The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. <i>Journal of Immunology</i> , <b>2009</b> , 183, 2729-40 <sup>5.3</sup>		39
20	Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder?. <i>American Journal of Epidemiology</i> , <b>2009</b> , 169, 749-55	3.8	110
19	Population-based lupus registries: advancing our epidemiologic understanding. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 1462-6		47
18	Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. <i>Journal of Autoimmunity</i> , <b>2009</b> , 33, 197-207	15.5	455
17	Delayed lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , <b>2008</b> , 67, 1044-6	2.4	20
16	Response to "Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury". <i>Oncologist</i> , <b>2008</b> , 13, 613-4; author reply 615-7	5.7	3

15	Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 1497-506		72
14	Incidence of systemic lupus erythematosus in the United Kingdom, 1990-1999. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 612-8		92
13	Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. <i>Blood</i> , <b>2007</b> , 110, 2907-15	2.2	207
12	Autoimmune diseases co-occurring within individuals and within families: a systematic review. <i>Epidemiology</i> , <b>2006</b> , 17, 202-17	3.1	121
11	Plasminogen activator inhibitor-1 is associated with impaired endothelial function in women with systemic lupus erythematosus. <i>Annals of the New York Academy of Sciences</i> , <b>2005</b> , 1051, 271-80	6.5	19
10	Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 2761-7		213
9	Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 53, 549-57		96
8	Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. <i>Blood</i> , <b>2004</b> , 103, 3677-83	2.2	188
7	Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. <i>Journal of Rheumatology</i> , <b>2004</b> , 31, 1763-7	4.1	81
6	Effects of cilostazol in patients with Raynaud's syndrome. <i>American Journal of Cardiology</i> , <b>2003</b> , 92, 1310-5	3.5	42
5	Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 48, 1992-2000		49
4	Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 1508-12	4.1	58
3	The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. <i>Journal of Immunology</i> , <b>2002</b> , 169, 6020-9	5.3	147
2	Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 2531-6	4.1	124
1	ISARIC Clinical Data Report issued: 14 July 2021		13